Pomegranate juice effects on cytochrome p450s expression: In vivo studies

Journal of Medicinal Food

Volumn 10, Issue 4, 2007, Pages 643-649

  Faria, Ana ^a,b   Monteiro, Rosário ^a,b   Azevedo, Isabel ^a   Calhau, Conceição ^a  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

CYP1A2; CYP2E1; CYP3A; CYP450; Food drug interactions; Pomegranate juice; Xenobiotic biotransformation

Indexed keywords

AFLATOXIN B1; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; PENTOBARBITAL; RNA;

ANIMAL EXPERIMENT; ARTICLE; BIOTRANSFORMATION; CANCER PREVENTION; CONTROLLED STUDY; ENZYME ACTIVITY; FOOD DRUG INTERACTION; FRUIT JUICE; LIVER; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POMEGRANATE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOBIOTIC METABOLISM;

ANIMALS; BEVERAGES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIET; FRUIT; GENE EXPRESSION; MALE; MICE; MICROSOMES, LIVER; PUNICACEAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

LYTHRACEAE; MUS;

EID: 37549060998     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2007.403     Document Type: Article

References (37)

1. Aviram M, Dornfeld L: Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis 2001;158:195-198.
2. Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J, Aviram M: Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr 2001;131:2082-2089.
3. Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H: Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci U S A 2005;102:14813-14818.
4. Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG, Heber D: In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 2005;16:360-367.
5. Adams LS, Seeram NP, Aggarwal BB, Takada Y, Sand D, Heber D: Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem 2006;54:980-985.
6. Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, Presser D, Fuhrman B: Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 2000;71:1062-1076.
7. Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA: Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000;48:4581-4589.
8. Rozenberg O, Howell A, Aviram M: Pomegranate juice sugar fraction reduces macrophage oxidative state, whereas white grape juice sugar fraction increases it. Atherosclerosis 2006;188:68-76.
9. Kaur G, Jabbar Z, Athar M, Alam MS: Punica granatum (pomegranate) flower extract possesses potent antioxidant activity and abrogates Fe-NTA induced hepatotoxicity in mice. Food Chem Toxicol 2006;44:984-993.
10. Perez-Vicente A, Gil-Izquierdo A, Garcia-Viguera C: In vitro gastrointestinal digestion study of pomegranate juice phenolic compounds, anthocyanins, and vitamin C. J Agric Food Chem 2002;50:2308-2312.
11. Sparreboom A, Cox MC, Acharya MR, Figg WD: Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-2503.
12. Obach RS: Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000;294:88-95.
13. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD: The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-326.
14. Hidaka M, Fujita K, Ogikubo T, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Arimori K: Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. Drug Metab Dispos 2004;32:581-583.
15. Patterson LH, Murray GI: Tumour cytochrome P450 and drug activation. Curr Pharm Des 2002;8:1335-1347.
16. Whitlock JP Jr: Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 1999;39:103-125.
17. Kushida H, Fujita K, Suzuki A, Yamada M, Endo T, Nohmi T, Kamataki T: Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase. Carcinogenesis 2000;21:1227-1232.
18. Guengerich FP: Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17.
19. Gordon GJ, Coleman WB, Grisham JW: Induction of cytochrome P450 enzymes in the livers of rats treated with the pyrrolizidine alkaloid retrorsine. Exp Mol Pathol 2000;69:17-26.
20. Pfohl-Leszkowicz A, Pinelli E, Bartsch H, Mohr U, Castegnaro M: Sex- and strain-specific expression of cytochrome P450s in ochratoxin A-induced genotoxicity and carcinogenicity in rats. Mol Carcinog 1998;23:76-85.
21. Omura T, Sato R: The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 1964;239:2379-2385.
22. Van Vleet TR, Bombick DW, Coulombe RA Jr: Inhibition of human cytochrome P450 2E1 by nicotine, cotinine, and aqueous cigarette tar extract in vitro. Toxicol Sci 2001;64:185-191.
23. Zacharova LY, Gulyaeva LF, Lyakhovich VV, Mikhailova ON, Timofeeva OA, Filipenko ML, Kaledin VI: Cytochrome P4501A1 and 1A2 gene expression in the liver of 3-methylcholanthrene-and o-aminoazotoluene-treated mice: a comparison between PAH-responsive and PAH-nonresponsive strains. Toxicol Sci 2003;73:108-113.
24. Kwon YH, Jovanovic A, Serfas MS, Tyner AL: The Cdk inhibitor p21 is required for necrosis, but it inhibits apoptosis following toxin-induced liver injury. J Biol Chem 2003;278:30348-30355.
25. Seree E, Villard PH, Hever A, Guigal N, Puyoou F, Charvet B, Point-Scomma H, Lechevalier E, Lacarelle B, Barra Y: Modulation of MDR1 and CYP3A expression by dexamethasone: evidence for an inverse regulation in adrenals. Biochem Biophys Res Commun 1998;252:392-395.
26. Peters SO, Bauermeister K, Simon JP, Branke B, Wagner T: Quantitative polymerase chain reaction-based assay with fluorogenic Y-chromosome specific probes to measure bone marrow chimerism in mice. J Immunol Methods 2002;260:109-116.
27. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
28. Bachmann KA: Genotyping and phenotyping the cytochrome p-450 enzymes. Am J Ther 2002;9:309-316.
29. Meyer UA: Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996;24:449-459.
30. Koch-Weser J, Greenblatt DJ: The archaic barbiturate hypnotics. N Engl J Med 1974;291:790-791.
31. Olsen RW: Drug interactions at the GABA receptor-ionophore complex. Annu Rev Pharmacol Toxicol 1982;22:245-277.
32. 2+ channel blockers on pentobarbital-induced hypnosis are influenced by serotonergic system. J Neural Transm 2006;113:1395-1402.
33. Navarro E, Alonso SJ, Martin FA, Castellano MA: Toxicological and pharmacological effects of D-arginine. Basic Clin Pharmacol Toxicol 2005;97:149-154.
34. Goloubkova TD, Heckler E, Rates SM, Henriques JA, Henriques AT: Inhibition of cytochrome P450-dependent monooxygenases by an alkaloid fraction from Helietta apiculata markedly potentiate the hypnotic action of pentobarbital. J Ethnopharmacol 1998;60:141-148.
35. Fukuda K, Guo L, Ohashi N, Yoshikawa M, Yamazoe Y: Amounts and variation in grapefruit juice of the main components causing grapefruit-drug interaction. J Chromatogr B Biomed Sci Appl 2000;741:195-203.
36. Xu C, Li CY, Kong AN: Induction of phase I, II and III drug metabolism/ transport by xenobiotics. Arch Pharm Res 2005;28:249-268.
37. Hidaka M, Okumura M, Fujita K, Ogikubo T, Yamasaki K, Iwakiri T, Setoguchi N, Arimori K: Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos 2005;33:644-648